Optimal treatment of metastatic colorectal cancer

References

• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. IARC, Lyon, France (2001).
   Google Scholar
• van de Velde CJH. Treatment of liver metastases of colorectal cancer. Ann. Oncol.16(Suppl. 2), ii114–ii149 (2005).
   Google Scholar
• Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Prauer H. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br. J. Surg.91, 1066–1071 (2004).
   PubMedGoogle Scholar
• Jaffe BM, Donaldson WL, Watson F, Spratt JS Jr. Factors influencing survival in patients with untreated hepatic metastases. Surg. Gynecol. Obstet.127, 1–11 (1968).
   PubMedGoogle Scholar
• Petrelli N, Douglas HO Jr, Herrera L et al. The modulation of fluorouracil by leucovorin in metastatic colorectal carcinoma: a prospective randomized Phase III trial. Gastrointestinal Tumor Study Group. J. Clin. Oncol.7, 1419–1426 (1989).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J. Clin. Oncol.15, 808–815 (1997).
   PubMed Web of Science ®Google Scholar
• Kelly H, Goldberg RM. Sistemic therapy for metastatic colrectal cancer: current options, current evidence. J. Clin. Oncol.23, 4553–4560 (2005).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with chemorefractory colorectal cancer that express the epidermal growth factor receptor. J. Clin. Oncol.22, 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Giantonio B, Catalano PJ, Meropol NJ et al. High dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from Eastern Cooperative Oncology Group (ECOG) study 3200. American Society of Clinical Oncology Annual Meeting, FL, USA, May 13–17, 2005.
   Google Scholar
• Poston GJ, Adam R, Alberts S et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J. Clin. Oncol.23, 7125–7134 (2005).
   PubMed Web of Science ®Google Scholar
• Adam R, Delvart V, Pascal G et al. Rescue surgery for uresecatable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg.240, 644–658 (2004).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22, 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Jamison RL, Donohue JH, Nagorney DM et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch. Surg.132, 505–510 (1997).
   PubMed Web of Science ®Google Scholar
• Figueras J, Valls C, Rafecas A et al. Resection rate and effect of post-operative chemotherapy on survival after surgery for colorectal liver metastases. Br. J. Surg.88, 980–985 (2001).
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.18, 136–147 (2000).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343, 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet355, 1041–1047 (2000).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment of advanced colorectal cancer. J. Clin. Oncol.18, 2938–2947 (2000).
   PubMed Web of Science ®Google Scholar
• Köhne C-H, Van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol.23, 4856–4865 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled study of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22, 23–30 (2004).
   PubMed Web of Science ®Google Scholar
• Rougier P, Van Cutsem E, Bajetta E et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet352, 1407–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet352, 1413–1418 (1998).
   PubMed Web of Science ®Google Scholar
• Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (FU)/folinic acid (FA) (Mayo) vs weekly high dose 24h 5FU/infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer. American Society of Clinical Oncology Annual Meeting, FL, USA, May 18–21, 2002.
   Google Scholar
• Rothemberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol.21, 2059–2069 (2003).
   PubMedGoogle Scholar
• O’Dwyer PJ, Johnson SW. Current status of oxaliplatin in colorectal cancer. Semin. Oncol.30, 78–87 (2003).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G et al. comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment on 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol.19, 2282–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenour fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol.19, 4097–4106 (2001).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero JM, Twelves C et al. XELOX (capecitabile plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol.22, 2084–2091 (2004).
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.21, 1307–1312 (2003).
   PubMed Web of Science ®Google Scholar
• Borner MM, Bernhard J, Dietrich D et al. A randomized Phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality of life, and toxicity. Ann. Oncol.16, 282–288 (2005).
   PubMed Web of Science ®Google Scholar
• Arkenau H, Kubicka S, Greil R et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis. Eur. J. Cancer160(Suppl. 3) (2005) (Abstract 601).
   Google Scholar
• Köhne C-H, de Greve C, Bokemeyer I et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first-line treatment of metastatic colorectal cancer: safety results of the prospective multicenter EORTC Phase III study 40015. American Society of Clinical Oncology Annual Meeting FL, USA, May 13–17 2005 (Abstract 3525).
   Google Scholar
• Douillard JY, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.20, 3605–3616 (2002).
   PubMed Web of Science ®Google Scholar
• Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.20, 3617–3627 (2002).
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol.23, 4866–4875 (2005).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J. Clin. Oncol.22, 1209–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest.95, 1789–1797 (1995).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86, 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Akiyama S, Yamada K et al. Angiogenesis as an unfavourable prognostic factor in human colorectal carcinoma. Cancer78, 226–231 (1996).
   PubMed Web of Science ®Google Scholar
• Choi HJ, Hyun MS, Jung GJ et al. Tumor angiogiogenesis is a prognostic predictor in colorectal carcinoma with special reference to the mode of metastasis and recurrence. Oncology55, 575–581 (1998).
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Jain RK et al. Direct evidence that VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat. Med.10, 145–147 (2004).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307, 58–629 (2005).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21, 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist10, 701–709 (2005).
   PubMed Web of Science ®Google Scholar
• Kabbinvar F, Schultz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil/leucovorin in first-line metastatic colorectal cancer: results from a randomized Phase II trial. J. Clin. Oncol.23, 3697–3705 (2005).
   PubMedGoogle Scholar
• Giantonio BJ, Levy D, O’Dweyer PJ et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer: updated results from the Eastern Cooperative Oncology Group (ECOG) Study 2200. Am. Soc. Clin. Oncol. Gastrointestinal Symposium, CA, USA, January 22–24, 2004.
   Google Scholar
• Hochster H, Welles L, Hart L et al. Bevacizumab in oxaliplatin-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized “TREE-2“ trial. Am. Soc. Clin. Oncol. Gastrointestinal Symposium, FL, USA. January 27–29, 2005.
   Google Scholar
• Chen HX, Mooney M, Boron L et al. Bevacizumab plus fluorouracil/leucovorin for advanced colorectal cancer that progressed after standard chemotherapies: an NCI Treatment Referral Center Trial (TCR0301). Proc. Am. Soc. Clin. Oncol.23, 249 (2004) (Abstract 3515).
   Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol.2, 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer92, 1331–1346 (2001).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JMV, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer37, S9–S15 (2001).
   PubMedGoogle Scholar
• Mendelson J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol.20, S1–S13 (2002).
   PubMedGoogle Scholar
• Ciardiello F, Totora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res.7, 2958–2970 (2001).
   PubMed Web of Science ®Google Scholar
• Saltz L, Rubin L, Hochester HS et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that express epidermal growth factor receptor. Proceedings of the American Society of Clinical Oncology.CA, USA, 12-15 May 2001. 20 (2001) (Abstract 7).
   Google Scholar
• Lenz H-J, Mayer PJ, Gold B. et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proceedings of the American Society of Clinical Oncology, LA, USA, 5–8 June 2004. 2 (2004) (Abstract 3510).
   Google Scholar
• Chung KY, Shia I, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23, 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bearzi I, Berardi R et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J. Clin. Oncol.22, 4772–47780 (2005).
   Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol.22, 5235–5241 (2005).
   Google Scholar
• Pippas AW, Lenz H-J, Mayer B. et al. Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. American Society of Clinical Oncology Annual Meeting, FL, USA, 13–17 May 2005 (Abstract 3595).
   Google Scholar
• Rosenberg AH, Loehrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). American Society of Clinical Oncology Annual Meeting, FL, USA, 18–21 May, 2002 (Abstract 536).
   Google Scholar
• Rougier P, Raoul J-L, Van Laethem M et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting, LA, USA, 5–8 June, 2004 (Abstract 3513).
   Google Scholar
• Folprecht G, Lutz MP, Schoffski P et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 17, 450–456 (2005).
   Google Scholar
• Diaz Rubio E, Tabernero J, van Cutsem E et al. Cetuximab in combination with oxaliplatin/5-fluorouracil(5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international Phase II study. American Society of Clinical Oncology Annual Meeting, FL, USA, 13–17 May, 2005 (Abstract 3535).
   Google Scholar
• Saltz L, Lenz H-J, Kindler H et al. Interim report of randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. American Society of Clinical Oncology Gastrointestinal Symposium, FL, USA, 27–29 January, 2005 (Abstract 169b).
   Google Scholar
• Hecht J, Patnaik A, Kindler H et al. ABX-EGF monotherapy in patients with metastatic colorectal cancer (mCRC): an updated analysis. American Society of Clinical Oncology Annual Meeting. LA, USA, June 5–8, 2004 (Abstract 3511).
   Google Scholar